Technique and results of "higher-dose" infusion.
We experimented with thrombolytic technique in an attempt to maximize therapeutic outcome, selecting urokinase because of its proven safety and efficacy in clinical investigation. An initially "high-dose" regimen, starting at 4,000 U/min and decreasing to 1,000 U/min after restoration of antegrade blood flow, generally establishes lysis within 3-4 h--even after acute embolic or thrombolytic occlusion. It can also be used effectively and safely as a therapeutic trial. "High-dose" urokinase compares favorably with "low-dose" streptokinase and shows a lower incidence of bleeding and allergic complications.
D001157:Arterial Occlusive Diseases / Q000188:drug therapy*; D005343:Fibrinolytic Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D006083:Graft Occlusion, Vascular / Q000188:drug therapy*; D006801:Humans; D007261:Infusions, Intra-Arterial; D013300:Streptokinase / Q000008:administration & dosage / Q000627:therapeutic use; D014568:Urokinase-Type Plasminogen Activator / Q000008:administration & dosage / Q000627:therapeutic use
D005343:Fibrinolytic Agents; D013300:Streptokinase; D014568:Urokinase-Type Plasminogen Activator